Marketing and campaigns · Financial performance · Technology and innovation ·
Novo Nordisk cuts the US list price of Wegovy by about half as a new pill widens its market
In February 2026 Novo Nordisk said that from January 2027 it would cut the US list price of Wegovy by about 50% and of Ozempic by about 35%. The move followed a pricing agreement with the US government and the launch of the first pill of its kind for weight loss, in a year Novo first expected its sales to fall.
- Published
- Sources checked
- Sources 8, all primary
- Where North America and Europe · Pharmaceuticals
A curated item, not a live report: it was checked on 20 November 2026 and does not update by itself. Later events may have changed the picture.
- The US list price of Wegovy, Ozempic and Rybelsus from 1 January 2027, for every dose Source [6]
- $675 a month
- Novo Nordisk's first outlook for adjusted sales growth in 2026, at constant exchange rates Source [5]
- −5% to −13%
- The same outlook, raised twice, by 4 November 2026 Source [8]
- −2% to +2%
Section 01: What happened?
Sourced facts only, each with the date it refers to and the document that states it.
Background
-
Novo Nordisk agreed with the US Administration to lower the prices of its semaglutide medicines, including Wegovy and Ozempic, from 2026 in Medicare Part D, Medicaid and the direct-to-patient cash channel, with Medicare coverage of obesity medicines through a pilot programme. It expected a negative low single-digit impact on its global sales growth in 2026, and said it was expected to receive a three-year tariff exemption.
Source: [1] Novo Nordisk A/S, press release of 6 November 2025
-
The White House said the prices of Ozempic and Wegovy bought through its TrumpRx website would fall from $1,000 and $1,350 a month respectively to $350, that their Medicare price would be $245 with a co-payment of $50 a month for beneficiaries, and that Novo Nordisk had committed an additional $10 billion of investment in the United States.
Source: [2] The White House, press release of 6 November 2025
-
The US Food and Drug Administration approved the Wegovy pill, a once-daily oral form of semaglutide, which Novo Nordisk described as the first oral GLP-1 treatment approved for weight management. In the OASIS 4 trial it showed a mean weight loss of 16.6% when treatment was adhered to.
Source: [3] Novo Nordisk A/S, press release of 22 December 2025
-
The Wegovy pill went on sale in the United States, with the starting dose at $149 a month through a self-pay offer, through more than 70,000 pharmacies, telehealth providers and Novo Nordisk's own NovoCare Pharmacy.
Source: [4] Novo Nordisk A/S, press release of 5 January 2026
-
Novo Nordisk reported sales growth of 10% and operating profit growth of 6% at constant exchange rates for 2025, and forecast adjusted sales growth of -5% to -13% for 2026. It expected sales to fall in the United States and cited lower realised prices, including the agreement with the US Administration, the loss of exclusivity for semaglutide in some international markets and intensifying competition.
Source: [5] Novo Nordisk A/S, press release of 3 February 2026
The development
-
Novo Nordisk announced that from 1 January 2027 it would lower the list price, or wholesale acquisition cost, of Wegovy, Ozempic and Rybelsus to $675 a month for all doses: a reduction of about 50% for Wegovy and about 35% for Ozempic.
Source: [6] Novo Nordisk A/S, press release of 24 February 2026
-
Jamey Millar, executive vice president for US operations, said private and public payers and patients had been calling for lower list prices, and that the cut was aimed at people whose out-of-pocket costs are linked to list price, such as those with high-deductible health plans or co-insurance.
Source: [6] Novo Nordisk A/S, press release of 24 February 2026
-
The company said the change would not affect its direct-to-patient self-pay prices, and described it as the latest in a series of efforts to widen access, including savings offers, self-pay through NovoCare Pharmacy and telehealth relationships.
Source: [6] Novo Nordisk A/S, press release of 24 February 2026
Since then
-
Novo Nordisk reported adjusted sales growth of 7% at constant exchange rates in the second quarter and raised its 2026 outlook to adjusted sales growth of 0% to -6%, driven by higher expectations for sales of its GLP-1 products. It also recorded impairment charges of DKK 6.3 billion on pipeline assets.
Source: [7] Novo Nordisk A/S, press release of 4 August 2026
-
With its third-quarter results, Novo Nordisk raised its 2026 outlook again, to adjusted sales growth of -2% to +2%. Its investor presentation reported more than 7 million prescriptions for the Wegovy pill in the year to date, about 90% of them self-pay, with about 80% of users new to GLP-1 obesity medicines, and said the pill had been launched in 8 markets.
Source: [8] Novo Nordisk A/S, company report of 4 November 2026
From here to the discussion question, the page gives the platform's reading of the facts above: the context, the concepts, the choices, the implications and the lessons. It is interpretation, not reporting, and it adds no new facts about the organizations.
Section 02: What is the business context?
The organization, its industry and the situation it was in, read from the facts above.
Novo Nordisk, a Danish company, makes semaglutide, the active ingredient of Ozempic for diabetes and Wegovy for obesity. In the United States the price of a medicine works on several levels: the list price, set by the maker; the net price insurers pay after rebates; and, increasingly, a self-pay price for patients who buy directly. Patients whose costs are tied to the list price, such as those on high-deductible plans, can pay far more than others for the same medicine.
By early 2026 Novo was under pressure from several directions at once. The US government had negotiated lower prices for Medicare and Medicaid; the patent on semaglutide had expired in some international markets; competition was intensifying; and Novo itself forecast that its adjusted sales would fall in 2026. Against that, the market for GLP-1 medicines was still growing, and Novo had a new product, a pill, priced to attract self-paying patients. The context is a market leader resetting its prices while trying to grow the market faster than prices fall.
Section 03: Which management concepts are relevant?
Where this development meets the IB course, and where it reaches beyond it, with links to the subtopics, terms, frameworks and tools that explain it.
In the IB course
-
4.5 The seven Ps of the marketing mix HL content
Price elasticity of demand decides whether a lower price raises revenue; here a list price cut, alongside self-pay and government prices.
-
Market growth and market share. The GLP-1 market kept expanding while competition for it intensified.
-
5.8 Research and development HL
A new form of an existing medicine, the pill, as innovation that reaches new patients as patents expire.
-
Patients, insurers, the US government and Novo's shareholders want different things from the price of the same medicine.
Key terms
Toolkit and frameworks
-
Ansoff matrix IB toolkit
Place each move on the matrix: new patients through Medicare coverage and self-pay channels, and a new product, the pill, in an existing market.
-
The product life cycle IB syllabus
As semaglutide's patents expire in some markets, a pill, a higher dose and new markets act as extension strategies.
- Named in the IB syllabus, guide p. 31
Work it through on the platform
-
Rework price, place and promotion for a medicine sold through insurers, government programmes and direct to patients.
Section 04: What choices did the organization face?
The realistic options, with the case for and against each. Where the organization's choice is known from the facts above, it is marked.
-
Keep list prices high and compete through confidential rebates to insurers
Protects the headline price and revenue per unit, but leaves patients whose costs follow the list price paying the most, at a time when payers, patients and the US government were pressing for lower prices.
-
Cut prices only in particular channels, such as government programmes and self-pay The option taken
Novo did this through its agreement with the US Administration and its self-pay offers. It targets the cuts, but does nothing for insured patients whose costs are linked to the list price.
-
Cut the list price for every dose The option taken
Widens access for patients on high-deductible plans and answers payers' calls, but lowers revenue per unit, so it pays only if volume grows enough. It takes effect from 1 January 2027.
-
Launch a new form of the medicine at a low self-pay price The option taken
The Wegovy pill, at $149 a month to start, reached patients who had not used GLP-1 medicines before, by Novo's own figures, but cheaper products risk taking sales from more expensive ones.
Section 05: What were the implications?
What followed, or may follow, for the organization, its stakeholders and its industry.
Revenue is price multiplied by volume, and Novo's decisions in 2026 test that arithmetic. Lower prices in government programmes and a list price cut reduce what Novo earns on each prescription; the question is whether volume grows fast enough to compensate. Novo's own outlook moved from a fall in adjusted sales of 5% to 13% in February to between a fall of 2% and a rise of 2% by November, driven by higher expectations for GLP-1 sales, which suggests that volume, helped by the pill, did more than Novo first expected.
The stakeholders gain and lose in different ways. Patients whose costs are tied to the list price should pay less from 2027; Medicare beneficiaries were promised coverage for obesity medicines through a pilot programme; shareholders face lower prices and, in some countries, competition after patent expiry. The pricing of medicines is also an ethical question: the price that maximizes revenue is not necessarily the price that serves patients, and governments increasingly set the terms. The marketing mix brief covers pricing strategies; this case shows several prices for one product, each set for a different customer.
Section 06: What can a student or manager learn?
- A price cut is a bet on price elasticity. Revenue rises only if volume grows by more than the price falls.
- One product can have several prices, a list price, a net price and a self-pay price, so always ask which price a customer actually pays.
- When patents expire and governments press on prices, innovation such as a new form or dose extends a product's life.
- For managers in regulated markets, prices are negotiated with powerful stakeholders, not set alone.
Section 07: Discussion question
Analyse how price elasticity of demand affects the likely impact of Novo Nordisk's US list price cut on its revenue.
Command term: Analyse (AO2). The platform's own question for discussion; it is not an IB examination question and has no official markscheme.
Section 08: The limits of the evidence
What the sources do not show, so that no one takes the analysis for more than it is.
- The list price cut takes effect on 1 January 2027, after this item was checked, so its effect cannot yet be seen.
- Every figure is Novo Nordisk's or the White House's own. The net prices insurers pay after rebates are not disclosed in the sources read.
- Novo's outlook ranges are forecasts of adjusted measures, which exclude some items, and they were changed twice during 2026.
Section 09: Sources
Every source was opened and read on the date shown. Each entry says which facts on this page it supports.
-
[1] Press release · Primary source
Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost (external site)
https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916450
Supports
- The agreement with the US Administration, the channels it covers, Medicare coverage through a pilot, the expected impact on 2026 sales growth and the expected tariff exemption.
A company announcement.
-
[2] Press release · Primary source
Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most-Favored-Nation Pricing to American Patients (external site)
https://www.whitehouse.gov/fact-sheets/2025/11/fact-sheet-president-donald-j-trump-announces-major-developments-in-bringing-most-favored-nation-pricing-to-american-patients/
Supports
- The TrumpRx and Medicare prices for Ozempic and Wegovy, the Medicare co-payment and Novo Nordisk's additional US investment.
A fact sheet published by the White House, the other party to the agreement.
-
[3] Press release · Primary source
Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management (external site)
https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916472
Supports
- The FDA's approval of the Wegovy pill, its description as the first oral GLP-1 for weight management and the OASIS 4 result.
A company announcement.
-
[4] Press release · Primary source
Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America (external site)
https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916475
Supports
- The US launch of the Wegovy pill, the $149 a month self-pay starting dose and the channels it is sold through.
-
[5] Press release · Primary source
Novo Nordisk releases 2026 sales and operating profit outlook (external site)
https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916482
Supports
- Sales and operating profit growth for 2025, the outlook for adjusted sales growth in 2026 and the reasons Novo gave for it.
A company announcement.
-
[6] Press release · Primary source
Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access (external site)
https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916504
Supports
- The new list price of $675 a month from 1 January 2027 and the reductions for Wegovy and Ozempic.
- The reasons given by the head of US operations, the unchanged self-pay prices and the other access efforts.
-
[7] Press release · Primary source
Novo Nordisk raises adjusted sales and adjusted operating profit outlook for 2026 (external site)
https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916589
Supports
- Adjusted sales growth in the second quarter of 2026, the raised outlook and its reason, and the impairment charges on pipeline assets.
A company announcement.
-
[8] Company report · Primary source
Investor presentation, Q3 2026 (external site)
https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/financial-results/2026/Q3-2026-full-presentation.pdf
Supports
- The outlook raised to adjusted sales growth of -2% to +2%, and the Wegovy pill's prescriptions, self-pay share, new users and launches in 8 markets.
The presentation's cover carries no date; its outlook table is dated 4 November 2026, the day Novo Nordisk published its results for the first nine months of 2026.
Arjun Agrawal | The Business Brief, https://the-business-brief-dun.vercel.app/intelligence/novo-nordisk-cuts-us-list-prices/. Original teaching material, not an IB publication. The organizations in the teaching cases are fictional unless a case says otherwise.